论文部分内容阅读
目的探讨采用重组人血管内皮抑制素联合化疗治疗晚期消化道肿瘤的临床疗效。方法回顾性分析本院于2011年2月~2013年4月收治的52例晚期消化道肿瘤患者的临床资料,按就诊顺序分为对照组和观察组,每组26例。对照组以常规化疗为主要治疗手段,观察组采用重组人血管内皮抑制素联合化疗进行治疗,比较两组治疗之后的疗效。结果对照组有9例缓解,占34.62%,5例稳定,占19.23%,12例进展,占46.15%,治疗有效率为53.85%;观察组有14例缓解,占53.85%,7例稳定,占26.92%,5例进展,占19.23%,治疗有效率为80.77%。在治疗有效率方面组间差异具有统计学意义(P<0.05)。结论重组人血管内皮抑制素联合化疗治疗晚期消化道肿瘤较为安全和有效,是一种值得临床借鉴和推广的治疗方案。
Objective To investigate the clinical efficacy of recombinant human endostatin combined with chemotherapy for advanced gastrointestinal tumors. Methods The clinical data of 52 patients with advanced gastrointestinal cancer treated in our hospital from February 2011 to April 2013 were retrospectively analyzed. According to the order of treatment, the patients were divided into control group and observation group, with 26 cases in each group. The control group with conventional chemotherapy as the main treatment, the observation group was treated with recombinant human endostatin combined with chemotherapy, compared the efficacy of the two groups after treatment. Results In the control group, 9 cases were relieved, accounting for 34.62%, 5 cases were stable, accounting for 19.23%, 12 cases were progressed, accounting for 46.15%, and the effective rate was 53.85%. In the observation group, 14 cases were relieved, accounting for 53.85% Accounting for 26.92%, 5 cases of progress, accounting for 19.23%, the effective treatment rate was 80.77%. There was a statistically significant difference in treatment efficiency between groups (P <0.05). Conclusion Recombinant human endostatin combined with chemotherapy for the treatment of advanced digestive tract tumors is safe and effective, which is worthy of clinical reference and promotion of treatment options.